125 related articles for article (PubMed ID: 37732525)
21. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
22. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
[TBL] [Abstract][Full Text] [Related]
23. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
24. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
van Ginkel N; Hermans TJN; Meijer D; Boormans JL; Voortman J; Mertens L; van Beek SC; Vis AN;
Int Urol Nephrol; 2022 Dec; 54(12):3145-3152. PubMed ID: 35997906
[TBL] [Abstract][Full Text] [Related]
25. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
[TBL] [Abstract][Full Text] [Related]
26. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study.
Gandaglia G; Popa I; Abdollah F; Schiffmann J; Shariat SF; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI; Sun M
Eur Urol; 2014 Sep; 66(3):561-8. PubMed ID: 24486024
[TBL] [Abstract][Full Text] [Related]
27. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder.
Stensland KD; Zaid H; Broadwin M; Sorcini A; Canes D; Galsky M; Moinzadeh A
Eur Urol Oncol; 2020 Aug; 3(4):509-514. PubMed ID: 31411987
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC.
Aldhaam NA; Elsayed AS; Jing Z; Richstone L; Wagner AA; Rha KH; Yuh B; Palou J; Khan MS; Menon M; Roupret M; Balbay D; Hosseini A; Wiklund P; Gaboardi F; Maatman TJ; Mottrie A; Wijburg C; Stöckle M; Hemal A; Kim E; Kaouk J; Hussein AA; Guru KA
J Urol; 2020 Jan; 203(1):57-61. PubMed ID: 31600114
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
31. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
[TBL] [Abstract][Full Text] [Related]
32. Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.
Omura M; Kikuchi E; Shigeta K; Ogihara K; Hakozaki K; Hara S; Shirotake S; Ide H; Yoshimine S; Ohigashi T; Mizuno R; Oya M
Jpn J Clin Oncol; 2022 Apr; 52(4):388-396. PubMed ID: 35106598
[TBL] [Abstract][Full Text] [Related]
33. Determinants of neoadjuvant chemotherapy for urothelial muscle-invasive bladder cancer: Does location matter?
Monaghan TF; Robins DJ; Suss NR; Miller CD; Flores VX; Smith MT; Weiss JP; McNeil BK; Winer AG
Int J Clin Pract; 2021 Aug; 75(8):e14262. PubMed ID: 33887115
[TBL] [Abstract][Full Text] [Related]
34. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
Lavery HJ; Stensland KD; Niegisch G; Albers P; Droller MJ
J Urol; 2014 Apr; 191(4):898-906. PubMed ID: 24300483
[TBL] [Abstract][Full Text] [Related]
35. Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
Tochigi K; Nagayama J; Bando S; Ishiyama A; Yuba T; Yuguchi Y; Matsui H; Hattori K; Gotoh M
Int J Urol; 2022 Nov; 29(11):1264-1270. PubMed ID: 35858759
[TBL] [Abstract][Full Text] [Related]
36. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
37. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
Duivenvoorden WC; Daneshmand S; Canter D; Lotan Y; Black PC; Abdi H; van Rhijn BW; Fransen van de Putte EE; Zareba P; Koskinen I; Kassouf W; Traboulsi SL; Kukreja JE; Boström PJ; Shayegan B; Pinthus JH
J Urol; 2016 Dec; 196(6):1627-1633. PubMed ID: 27312316
[TBL] [Abstract][Full Text] [Related]
38. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.
Park JC; Gandhi NM; Carducci MA; Eisenberger MA; Baras AS; Netto GJ; Liu JJ; Drake CG; Schoenberg MP; Bivalacqua TJ; Hahn NM
J Urol; 2016 Apr; 195(4 Pt 1):880-5. PubMed ID: 26598426
[TBL] [Abstract][Full Text] [Related]
40. Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
Gopalakrishnan D; Elsayed AS; Hussein AA; Jing Z; Li Q; Wagner AA; Aboumohamed A; Roupret M; Balbay D; Wijburg C; Stockle M; Dasgupta P; Khan MS; Wiklund P; Hosseini A; Peabody J; Shigemura K; Trump D; Guru KA; Chatta G
Int J Urol; 2022 Mar; 29(3):197-205. PubMed ID: 34923677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
